| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Improved tonic bitters | US86551D | US86551A | 1869-02-02 | ||
| 82 | Improved medical compound | US67657D | US67657A | 1867-08-13 | ||
| 83 | mitchell | US64787D | US64787A | 1867-05-14 | ||
| 84 | Improved medical compound | US54304D | US54304A | 1866-05-01 | ||
| 85 | Medical compound | US28904D | US28904A | 1860-06-26 | ||
| 86 | Use of essential oils to increase bioavailability of orally administered pharmaceutical compounds | US19936 | 1998-02-06 | US6121234A | 2000-09-19 | Leslie Z. Benet; Vincent J. Wacher; Reed M. Benet |
| A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4. | ||||||
| 87 | Local oral herbal slow release tablets | US904248 | 1997-07-31 | US5942244A | 1999-08-24 | Michael Friedman; Orna Levin; Yochanan Forman; Doron Friedman |
| A tablet for the local and slow release of herbal medication into the oral cavity of a subject. Also provided is a method of making the tablet and a method of using the tablet. The tablet includes a pharmaceutically effective amount of a herbal medication, a polymeric matrix material such as ethyl cellulose, a release enhancer such as PEG 4000 and a filler such as lactose. The tablet is characterized by long dissolution times of up to 120 minutes. | ||||||
| 88 | Method and composition for treatment of diabetes | US924512 | 1997-09-05 | US5886029A | 1999-03-23 | Kirpal S. Dhaliwal |
| A medicinal composition is provided for treatment of diabetes in a human subject. The medicinal composition of the invention induces a significant reduction in serum glucose due to the regeneration of pancreatic islet cells. A medicinal composition according to the invention necessarily includes a pharmacologically significant quantity of (-)epicatechin augmented with a comparable amount of gymnemic acid. For best results smaller quantities of cinnamomum tamala, syzygium cumini, trigonella foenum graceum, azardichta indica, ficus racemosa, and tinospora cordifolia are also included in the composition. One to two grams of the medicinal composition of the invention are administered to a diabetic human subject three times a day before meals. The unique combination of components in the medicinal composition leads to a regeneration of the pancreas cells which then start producing insulin on their own. Since the composition restores normal pancreatic function, treatment can be discontinued after between about four and twelve months. | ||||||
| 89 | Use of odorants to treat male impotence, and article of manufacture therefor | US606544 | 1996-02-23 | US5885614A | 1999-03-23 | Alan R. Hirsch |
| A method is provided for inducing or enhancing penile erection through the delivery of odorants for inhalation. The administration of odorants provides an increase in blood flow to the penis, and a therapeutic aid to stimulate sexual activity and alleviate male vasculogenic impotence. | ||||||
| 90 | Nasal spray having a mineral vitamin component, a mineral component and aloe vera | US803535 | 1997-02-20 | US5840278A | 1998-11-24 | Thomas Coleman |
| An aqueous nasal spray formulation contains a vitamin component, a mineral component, a aloe vera in a water based solvent. The vitamin component contains Vitamin C, Rose Hips, Acerola, Lemon Bioflavanoids, Hesperidin, Rustin and Vitamin B.sub.6. The mineral component contains potassium, calcium, magnesium, zinc and manganese. In the formulation, the vitamin component accounts for 25-40% by volume of the formulation, the mineral component is from 11-12% by volume and the aloe vera is from 8-12% by volume of the formulation. | ||||||
| 91 | Use of essential oils to increase bioavailability of oral pharmaceutical compounds | US478207 | 1995-06-07 | US5716928A | 1998-02-10 | Leslie Z. Benet; Vincent J. Wacher; Reed M. Benet |
| A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250/.mu.g rat liver microsomes, 1.mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1M sodium phosphate buffer, pH 7.4. | ||||||
| 92 | Method of treating a patient suffering from a viral infection | US465351 | 1995-06-05 | US5698524A | 1997-12-16 | Walter Mach, deceased; by Chantal Mach, legal representative |
| A method of treating a patient suffering with a viral infection (such as HIV) by administering to the patient an effective anti-viral amount of a composite molecular active substance group, which is produced by the process comprising: (a) preparing lignin units by carrying out an extraction in an aqueous media under weakly acidic or alkaline conditions of wood or wood-like materials and/or plant-cell cultures and separating-off the resultant insoluble solids; (b) preparing lignoid units by carrying out an aqueous alkaline extraction at a pH of 7 to 14 of starting materials selected from the group consisting of wood-incarbonization products and bioconverted wood-like materials and separating-off the resultant alkali-insoluble solids; and (c) preparing a water-soluble mixed polymer by reacting the lignin units from step (a) with the lignoid units from step (b), under aqueous alkaline isolating by ultrafiltration a low molecular weight fraction having a molecular weight of no more than 3000 daltons of the mixed polymer, taking a cut between 15 to 40 kilodaltons and discarding the resultant residue, and treating the resultant solution with an H.sup.+ cation exchanger at a pH of 3 to 7. | ||||||
| 93 | Hardening agent for affected tissues of the digestive system | US86853 | 1993-07-07 | US5470589A | 1995-11-28 | Zhao-Qi Shi |
| The hardening agent contains a composition comprised of tannic acid and potassium aluminium sulfate in a ratio of tannic acid to potassium aluminium sulfate ranging from 10 to 1 to 1 to 50 and a stabilizing agent extracted from crude drugs of plants containing a phenol, flavon, flavonoid, catechin or a polycarboxylic acid. | ||||||
| 94 | Cosmetic composition | US174202 | 1993-12-27 | US5468492A | 1995-11-21 | Erzsebet Szaloki; Ilona Kristof; Veronika Pal; Eva Szabo |
| A topical cosmetic composition of an extract of a hair fallout reducing effective amount of Gingko biloba (maidenhair tree) leaves, and an extract of the root of Liquiritia officinalis (sweet-root), and one or more cosmetically acceptable solid or liquid carrier, and optionally one or more cosmetically acceptable supplementary ingredient. | ||||||
| 95 | Pharmaceutical liquid composition containing Bezoar bovis | US878215 | 1992-05-04 | US5225203A | 1993-07-06 | Young S. Kim |
| A pharmaceutical liquid composition such as suspension, gel, or sol preparation, contains Bezoar bovis, Dioscoreae rhizoma, Glycyrrhizae radix, Ginseng radix, Typhae Pollen, Massa medicata fermentata, Sojae germinatum Semen, Cinnamomi cortex, Gelatin, Paeoniae radix liriopis Tuber, Scutellariae radix, Angelicae gigantis radix, Ledebouriellae radix, Atractylodis rhizoma alba, Bupleuri radix, Platycodi radix, Armeniacae Semen, Hoelen, Cnidii rhizoma, Antellopis cornu, Moschus, Borneol, Ampelopsis radix, and Zingiberis rhizoma for easy oral and parental administration thereof to critical patients. | ||||||
| 96 | Pharmaceutical liquid composition containing bezoar bovis and preparation for its manufacture | US595671 | 1990-10-11 | US5133964A | 1992-07-28 | Young S. Kim |
| A pharmaceutical liquid composition prepared by combining a predetermined quantity of natural substances from the genera Glycyrrhizae Radix, Ginseng Radix, Typhae Pollen, Massa Medicata Fermentata, Sojae germinatum Semen, Cinnamomi Cortex, Paeoniae Radix, Liriope Tuber, Scutellariae Radix, Angelicae Gigantis Radix, Ledebouriellae Radix, Atractylodis Rhizoma Alba, Bupleuri Radix, Platycodi Radix, Armeniacae Semen, Hoelen, Cnidii Rhizoma, Antellopis Cornu, Ampelopsis Radix, Zingiberis Rhizoma, and Dioscoreae Rhizoma and cutting the natural substances into microparticle size or extracting the natural substances with water or alcohol to form a first microparticle product or extracts; providing a predetermined quantity of natural substances from the genera Bezoar Bovis, Moschus, and Borneol and cutting the natural substances into microparticle size to form a second microparticle product; providing a Gelatin solution; mixing the first microparticle product or extract with the second microparticle product and Gelatin solution; and preparing the mixture with water or alcohol to produce a pharmaceutical liquid composition for orally administering to patients such as infants, children, critical patients, and the like. | ||||||
| 97 | Process for preparation of aloe products products, produced thereby and compositions thereof | US869261 | 1986-06-05 | US4735935A | 1988-04-05 | Bill H. McAnalley |
| Process for producing aloe extracts including the separation of the leaves of the aloe plant into distinct portions. In particular, a first process is described for producing an aloe extract which is substantially free of anthraquinone-rich yellow sap and a second process is described for extracting the active chemical substance in the aloe plant.The active chemical substance in the aloe plant is extracted from aloe leaves and its characteristic properties are described. | ||||||
| 98 | Curative and preventive agent for ulcers of digestive organs | US875529 | 1986-06-20 | US4732760A | 1988-03-22 | Yoshiro Iga; Kanemichi Okano; Toshiaki Akira |
| A curative and preventive agent for ulcers of digestive organs comprising as the main constituent an active component having anti-ulcer activity derived from a hot-water, an alcohol or a water-alcohol mixed solution extract of cassia buds. | ||||||
| 99 | Preparation for reducing cancer symptoms without treating cancer | US701458 | 1985-02-14 | US4618495A | 1986-10-21 | Hiromichi Okuda; Hiroshi Masuno; Masaki Aburada; Shigefumi Takeda; Eiko Itoh; Moe Matsushita; Eikichi Hosoya |
| A composition for reducing cancer symptoms by improving lipid metabolism and eliminating or reducing anorexia in tumor-bearing patients through inhibition of the lipid degradation-promoting action of toxohormone L which comprises an aqueous or aqueous organic solvent extract of one or more crude preparations selected from the group consisting of Astragali radix, Cinnamomi cortex, Rehmanniae radix, Paeoniae radix, Cnidii rhizoma, Atractylodis lanceae rhizoma, Angelicae radix, Ginseng radix, Hoelen and Glycyrrhizae radix, a method for preparing such a composition, and a method for reducing cancer symptoms using the composition. | ||||||
| 100 | Adminiculum for antitumor agents | US509197 | 1983-06-29 | US4613591A | 1986-09-23 | Masaki Aburada; Shigefumi Takeda; Eiko Itoh; Moe Matsushita; Eikichi Hosoya |
| Adminiculum increasing the antitumor activities of mitomycin C and doxorubicin hydrochloride and decreasing the side effects associated with their use comprising an aqueous or aqueous organic solvent extract of a crude preparation of Astragali radix, Cinnamomi cortex, Rehmanniae radix, Paeoniae radix, Cnidii rhizoma, Atractylodis lanceae rhizoma, Angelicae radix, Ginseng radix, Hoelen and Glycyrrhizae radix, a method for preparing said adminiculum and a method for its use. In addition, compositions and methods for treating tumor-bearing patients are disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈